On Tuesday, Nautilus Biotechnology Inc (NASDAQ: NAUT) was 16.32% up from the session before settling in for the closing price of $1.9. A 52-week range for NAUT has been $0.62 – $2.51.
A company in the Healthcare sector has dropped its sales by -4.55% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at 6.25%. With a float of $60.06 million, this company’s outstanding shares have now reached $126.31 million.
Nautilus Biotechnology Inc (NAUT) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Nautilus Biotechnology Inc stocks. The insider ownership of Nautilus Biotechnology Inc is 52.45%, while institutional ownership is 25.80%. The most recent insider transaction that took place on Nov 06 ’25, was worth 5,960. In this transaction Chief Marketing Officer of this company bought 4,000 shares at a rate of $1.49, taking the stock ownership to the 4,000 shares. Before that another transaction happened on Sep 05 ’25, when Company’s CEO, President, and Secretary bought 116,500 for $0.67, making the entire transaction worth $78,544. This insider now owns 10,258,221 shares in total.
Nautilus Biotechnology Inc (NAUT) Performance Highlights and Predictions
Going through the last 3-months fiscal report unveiled on the 12/31/2024, it has been observed that the corporation posted -0.14 earnings per share (EPS) during the time that was better than consensus figure (set at -0.16) by 0.02. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.17 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 6.25% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -1.75% during the next five years compared to -4.55% drop over the previous five years of trading.
Nautilus Biotechnology Inc (NASDAQ: NAUT) Trading Performance Indicators
You can see what Nautilus Biotechnology Inc (NAUT) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 14.95.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.50, a number that is poised to hit -0.14 in the next quarter and is forecasted to reach -0.61 in one year’s time.
Technical Analysis of Nautilus Biotechnology Inc (NAUT)
Let’s dig in a bit further. During the last 5-days, its volume was 0.42 million. That was better than the volume of 0.29 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 85.43%.
During the past 100 days, Nautilus Biotechnology Inc’s (NAUT) raw stochastic average was set at 97.55%, which indicates a significant increase from 95.88% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.2200 in the past 14 days, which was higher than the 0.0900 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.1500, while its 200-day Moving Average is $0.9500. However, in the short run, Nautilus Biotechnology Inc’s stock first resistance to watch stands at $2.3600. Second resistance stands at $2.5000. The third major resistance level sits at $2.7600. If the price goes on to break the first support level at $1.9600, it is likely to go to the next support level at $1.7000. Assuming the price breaks the second support level, the third support level stands at $1.5600.
Nautilus Biotechnology Inc (NASDAQ: NAUT) Key Stats
There are 126,305K outstanding shares of the company, which has a market capitalization of 279.13 million. As of now, sales total 0 K while income totals -70,780 K. Its latest quarter income was 0 K while its last quarter net income were -13,570 K.
